Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Sarepta Therapeutics' Long-Term Potential Is in Flux

TheMotleyFool

0 0

Sarepta Therapeutics' Long-Term Potential Is in FluxPhoto, wide shot, wide-angle lens, Medical device manufacturer, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/3a7f6312-1eee-4702-9005-93cc1e62f970.png

Sarepta Therapeutics (NASDAQ: SRPT) continues to make progress selling its drugs to treat Duchenne muscular dystrophy (DMD). But the biotech's valuation is still largely based on its potential to treat a large portion of DMD patients with its gene therapy SRP-9001. In this video from Motley Fool Live, recorded on March 8, Fool.com contributors Brian Orelli and Keith Speights discuss Sarepta's fourth-quarter results and why investors should still be focused on the company's pipeline.

Source Fool.com

Like: 0

SRPT

Share